- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00061867
Liposomal Doxorubicin and Thermal Therapy in Treating Patients With Prostate Cancer
A Dose Escalation, Pharmacokinetics, and Safety Study of Doxorubicin Encapsulated in Temperature Sensitive Liposomes Released Through Microwave Therapy in the Treatment of Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as liposomal doxorubicin, use different ways to stop tumor cells from dividing so they stop growing or die. Microwave thermotherapy kills tumor cells by heating them to several degrees above body temperature. Combining liposomal doxorubicin with microwave thermotherapy may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of liposomal doxorubicin when given together with microwave thermotherapy in treating patients with prostate cancer.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
- Determine the maximum tolerated dose of doxorubicin HCl liposome released through thermal microwave therapy in patients with adenocarcinoma of the prostate.
- Determine the pharmacokinetics and biodistribution profile of this drug in these patients.
- Determine the safety profile and dose-limiting toxicity of this drug in these patients.
- Determine the clinical response in patients treated with this regimen.
OUTLINE: This is an open-label, dose-escalation, multicenter study.
Patients receive doxorubicin HCl liposome IV over 30 minutes. Patients then undergo a 60-minute course of prostate thermotherapy. Treatment may repeat every 28-42 days for up to 6 courses, at the discretion of the physician.
Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.
Patients are followed at 8, 15, 30, and 90 days.
PROJECTED ACCRUAL: Approximately 50 patients will be accrued for this study.
Study Type
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Louisiana
-
Shreveport, Louisiana, United States, 71106
- Regional Urology, L.L.C.
-
-
South Carolina
-
Myrtle Beach, South Carolina, United States, 29572
- Grand Strand Urology LLP
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
- Histologically confirmed adenocarcinoma of the prostate
- Rising prostate-specific antigen AND radiographic evidence of extraprostatic prostate cancer by bone scan, CT scan, prostascint scan, or MRI
PATIENT CHARACTERISTICS:
Age
- 40 and over
Performance status
- Karnofsky 80-100%
Life expectancy
- Not specified
Hematopoietic
- WBC greater than 4,000/mm^3
- Platelet count greater than 100,000/mm^3
- Hemoglobin greater than 10.0 g/dL
Hepatic
- Bilirubin normal
- AST normal
- Alkaline phosphatase normal
- No acute or chronic liver disease
Renal
- Creatinine less than 1.5 times upper limit of normal
Cardiovascular
- Ejection fraction at least 50% by MUGA
- EKG normal
- No myocardial infarction or cerebral vascular accident within the past 6 months
- No life threatening cardiac arrhythmias
- No congestive heart failure
- No cardiac pacemaker
- No peripheral arterial disease with intermittent claudication or Leriches syndrome (i.e., claudication of the buttocks or perineum)
Other
- Fertile patients must use effective barrier contraception during and for 3 months after study participation
- No sperm donation during and for 3 months after study participation
- Not febrile
- No interest in future fertility or fathering children
- No significantly decreased pain response
- No severe urethral stricture
- No protruding median lobe resulting in a "ball-valve" type of obstruction at the bladder neck
- No major psychiatric illness that would prevent informed consent
- No major psychiatric illness that required inpatient treatment within the past 3 months
- No psychological, family, sociological, or geographic condition that would preclude study compliance
- No allergy to eggs or egg products
- No urinary or prostatic infection
- No full urinary retention
- No penile or urinary sphincter implant
- No metallic implants in the pelvic or femoral area
- No other serious medical illness that would preclude study participation
PRIOR CONCURRENT THERAPY:
Biologic therapy
- No concurrent live vaccines
Chemotherapy
- No prior anthracycline
- No concurrent streptozocin
Endocrine therapy
- No concurrent hormonal therapy (except luteinizing hormone-releasing hormone analog)
- No concurrent glucocorticoids administered at more than physiologic replacement doses (other than as an antiemetic)
Radiotherapy
- Not specified
Surgery
- More than 3 months since prior major surgery
Other
- No prior therapy that resulted in permanent reduction of pain response (e.g., prior surgery, regional or local anesthetic)
- No concurrent PC-SPES
- No concurrent cyclosporine, phenobarbital, or phenytoin
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Masking: None (Open Label)
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Catherine Van Doren, RN, Imunon
Study record dates
Study Major Dates
Study Start
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Male
- Prostatic Diseases
- Prostatic Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Doxorubicin
- Liposomal doxorubicin
Other Study ID Numbers
- CELSION-10302101
- CDR0000301761 (Registry Identifier: PDQ (Physician Data Query))
- RPCI-DS-0228
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostate Cancer
-
Roswell Park Cancer InstituteRecruitingObesity | Overweight | Cancer Survivor | Prostate Adenocarcinoma | Stage I Prostate Cancer | Stage II Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage A Prostate Cancer | Stage... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Regeneron Pharmaceuticals; Prostate Cancer FoundationWithdrawnStage III Prostate Cancer | Stage IV Prostate Cancer | Stage IVA Prostate Cancer | Stage IVB Prostate Cancer | Stage IIIA Prostate Cancer | Stage IIIB Prostate Cancer | Stage IIIC Prostate Cancer
-
Jonsson Comprehensive Cancer CenterProgenics Pharmaceuticals, Inc.TerminatedRandomized Trial of PSMA PET Scan Before Definitive Radiation Therapy for Prostate Cancer (PSMA-dRT)Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate Cancer AJCC v8 | Stage I Prostate...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); SanofiTerminatedDiarrhea | Recurrent Prostate Cancer | Hormone-resistant Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ryan Kohlbrenner, MDRadiological Society of North AmericaCompletedProstate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage...United States
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnStage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8 | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage IIC Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Stage IIA Prostate Cancer AJCC v8 | Stage IIB Prostate...United States
-
Barbara Ann Karmanos Cancer InstituteGenentech, Inc.CompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
Ohio State University Comprehensive Cancer CenterRiverside Methodist HospitalCompletedStage I Prostate Cancer | Stage III Prostate Cancer | Stage IV Prostate Cancer | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
-
University of California, IrvineCompletedRecurrent Prostate Cancer | Stage I Prostate Cancer | Stage III Prostate Cancer | Adenocarcinoma of the Prostate | Stage IIA Prostate Cancer | Stage IIB Prostate CancerUnited States
Clinical Trials on hyperthermia treatment
-
Roswell Park Cancer InstituteCompletedMelanoma | Soft Tissue Sarcoma | Breast Carcinoma | Lung Carcinoma | Malignant Neoplasm | Colon Carcinoma | Ovarian Neoplasm | Malignant Head and Neck Neoplasm | Adult Liver Carcinoma | Kidney NeoplasmUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Active, not recruitingRecurrent Prostate CarcinomaUnited States
-
University of ZurichNot yet recruitingMajor Depressive Disorder
-
Charite University, Berlin, GermanyRecruitingRefractory Metastatic Colorectal CancerGermany
-
Charite University, Berlin, GermanyRecruiting
-
Thomas Jefferson UniversityAstraZenecaActive, not recruitingRecurrent Breast Carcinoma | Metastatic Malignant Neoplasm in the Chest WallUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Unknown
-
Mark DewhirstWithdrawn
-
Fachklinik Hornheide an der Universität MünsterUnknownAdvanced Metastastic Malignant Melanoma | Refractory to First-Line Chemotherapy Irresectable Progressive Soft Tissue MetastasesGermany